Pain and immunity

Joint Bone Spine

Volumn 79, Issue 3, 2012, Pages 228-236

  Guillot, Xavier ^a,b   Semerano, Luca ^a,b   Decker, Patrice ^a   Falgarone, Géraldine ^a,b   Boissier, Marie Christophe ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Allodynia; Dorsal horn; Dorsal root ganglion; Glial cell; IL 1 ; Integrated network; Matrophage; Neuroimmune synapse; Neuron; Neuropathic pain; Nociceptors; Plasticity; Reciprocal communication; Resolvins; Sensitization; T cell; T cell receptor; TNF

Indexed keywords

BRADYKININ; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; CATHEPSIN S; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; STAT3 PROTEIN; SUBSTANCE P; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ASTROCYTE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; COMPLEMENT SYSTEM; DISEASE EXACERBATION; GLIA CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; INFLAMMATORY PAIN; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MICROGLIA; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NEUTROPHIL; NOCICEPTIVE RECEPTOR; NONHUMAN; PAIN; SCHWANN CELL; SENSITIZATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SPINAL CORD DORSAL HORN;

CHRONIC PAIN; HUMANS; INFLAMMATION; NEURALGIA; NEUROIMMUNOMODULATION; NEURONAL PLASTICITY; NOCICEPTORS;

EID: 84860575066     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.10.008     Document Type: Short Survey

References (60)

1. Javier R.M., Perrot S. Do men and women experience pain differently? What are the implications for the rheumatologist?. Joint Bone Spine 2010, 77:198-200.
2. Demoulin C., Grosdent C., Capron L., et al. Effectiveness of a semi-intensive multidisciplinary outpatient rehabilitation program in chronic low back pain. Joint Bone Spine 2010, 77:58-63.
3. Scholz J., Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007, 10:1361-1368.
4. Ren K.E., Dubner R. Interactions between the immune and nervous systems in pain. Nat Med 2010, 16:1267-1276.
5. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7:179-190.
6. Folgueras A.R., Valdes-Sanchez T., Llano E., et al. Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation. Proc Natl Acad Sci U S A 2009, 106:16451-16456.
7. Rudick C.N., Bryce P.J., Guichelaar L.A., et al. Mast cell-derived histamine mediates cystis pain. PLoS One 2008, 3:e2096.
8. Wolf G., Gabay E., Tal M., et al. Genetic impairment of interleukin-1 signaling attenuates neuropathic pain, autonomy, and spontaneous ectopic neuronal activity, following nerve injury in mice. Pain 2006, 120:315-324.
9. Kiguchi N., Maeda T., Kobayashi Y., et al. Macrophage inflammatory protein-1α mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1 beta up-regulation. Pain 2010, 149:305-315.
10. Shubayev V.I., Angert M., Dolkas J., et al. TNFα-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve. Mol Cell Neurosci 2006, 31:407-415.
11. Ting E., Guerrero A.T.G., Cunha T.M., et al. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol 2008, 153:1043-1053.
12. Jang J.H., Clark J.D., Li X., et al. Nociceptive sensitization by complement C5a and C3a in mouse. Pain 2010, 148:343-352.
13. Costigan M., Moss A., Latremoliere A., et al. T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J Neurosci 2009, 29:14415-14422.
14. Moalem G., Xu K., Yu L. T lymphocytes play a role in neuropathic pain following peripheral nerve injury in rats. Neuroscience 2004, 129:767-777.
15. Cunin P., Caillon A., Corvaisier M., et al. The tachykinins substance P and hemokinin-1 favor the generation of human memory Th17 cells by inducing IL-1β, IL-23, and TNF-like 1A expression by monocytes. J Immunol 2011, 186:4175-4182.
16. Lindholm D., Heumann R., Meyer M., et al. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature 1987, 330:658-659.
17. Esper R.M., Loeb J.A. Rapid axoglial signaling mediated by neuregulin and neurotrophic factors. J Neurosci 2004, 24:6218-6227.
18. Fernandes E.S., Russell F.A., Spina D., et al. A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor α-induced inflammatory hyperalgesia and Freund's complete adjuvant-induced monoarthritis. Arthritis Rheum 2011, 63:819-829.
19. Krämer H.H., He L., Lu B., et al. Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis 2009, 35:177-183.
20. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
21. Milligan E.D., Watkins L.R. Pathologic and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36.
22. White F.A., Bhangoo S.K., Miller R.J. Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov 2005, 4:834-844.
23. Tanga F.Y., Nutile-McMenemy N., DeLeo J.A. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A 2005, 102:5856-5861.
24. Kim D., Kim M.A., Cho I.H., et al. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem 2007, 282:14975-14983.
25. Hutchinson M.R., Zhang Y., Brown K., et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 2008, 28:20-29.
26. Clark A.K., Yip P.K., Grist J., et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A 2007, 104:10655-10660.
27. Zhang J., Shi X.Q., Etcheverry S., et al. Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci 2007, 27:12396-12406.
28. Zhuang Z.Y., Gerner P., Woolf C.J., et al. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114:149-159.
29. Calvo M., Zhu N., Tsantoulas C., et al. Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury. J Neurosci 2010, 30:5437-5450.
30. Nie H., Weng H.R. Glutamate transporters prevent excessive activation of NMDA receptors and extrasynaptic glutamate spillover in the spinal dorsal horn. J Neurophysiol 2009, 101:2041-2051.
31. Griffin R.S., Costigan M., Brenner G.J., et al. Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci 2007, 27:8699-8708.
32. Dominguez E., Mauborgne A., Mallet J., et al. SOCS3-mediated blockade of JAK/STAT3 signaling pathway reveals its major contribution to spinal cord neuroinflammation and mechanical allodynia after peripheral nerve injury. J Neurosci 2010, 30:5754-5766.
33. Clark A.K., Staniland A.A., Marchand F., et al. P2X7-dependant release of interleukin-1β and nociception in the spinal cord following lipopolysaccharide. J Neurosci 2010, 30:573-582.
34. Kawasaki Y., Xu Z.Z., Wang X., et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14:331-336.
35. Zhou Z., Peng X., Hagshenas J., et al. A novel cell-cell signaling by microglial transmembrane TNFα with implications for neuropathic pain. Pain 2010, 151:296-306.
36. Choi J.I., Svensson C.I., Koehrn F.J., et al. Peripheral inflammation induces tumor necrosis factor dependant AMPA receptor trafficking and Akt phosphorylation in spinal cord in addition to pain behavior. Pain 2010, 149:243-253.
37. Hess A., Axmann R., Rech J., et al. From the cover: blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A 2011, 108:3731-3736.
38. Miyoshi K., Obata K., Kondo T., et al. Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury. J Neurosci 2008, 28:12775-12787.
39. Jessop D.S., Fassold A., Wolff C., et al. Endomorphins in rheumatoid arthritis, osteoarthritis, and experimental arthritis. Ann N Y Acad Sci 2010, 1193:117-122.
40. Soderquist R.G., Sloane E.M., Loram L.C., et al. Release of plasmid DNA encoding IL-10 from PGLA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res 2010, 27:841-854.
41. Valenzano K.J., Tafesse L., Lee G., et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005, 48:658-672.
42. Suzuki T., Hide I., Ido K., et al. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor activated microglia. J Neurosci 2004, 24:1-7.
43. Xu Z.H., Zhang L., Liu T., et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 2010, 16:592-597.
44. Serhan C.N., Chiang N., van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361.
45. Tsuda M., Shigemoto-Mogami Y., Koizumi S., et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424:778-783.
46. McGaraughty S., Jarvis M.F. Antinociceptive properties of a non-nucleotide P2X3/P2X2/3 receptor antagonist. Drug News Perspect 2005, 18:501-507.
47. Donnelly-Roberts D.L., Jarvis M.F. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 2007, 151:571-579.
48. Zemke D., Majid A. The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 2004, 27:293-298.
49. Tawfik V.L., Nutile-McMenemy N., LaCroix-Fralish M.L., et al. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun 2007, 21:238-246.
50. Hutchinson M.R., Lewis S.S., Coats B.D., et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 2009, 23:240-250.
51. Gao Y.J., Xu Z.Z., Liu Y.C., et al. The c-Jun N-terminal kinase 1 (JNK1) in spinal astrocytes is required for the maintenance of bilateral mechanical allodynia under a persistent inflammatory pain condition. Pain 2010, 148:309-319.
52. Gomez-Nicola D., Valle-Argos B., Suardiaz M., et al. Role of IL-15 in spinal cord and sciatic nerve after chronic constriction injury: regulation of macrophage and T-cell infiltration. J Neurochem 2008, 107:1741-1752.
53. Hao S., Mata M., Glorioso J.C., et al. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther 2007, 14:1010-1016.
54. Torres R., Macdonald L., Croll S.D., et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 2009, 68:1602-1608.
55. Terkeltaub R., Sundy J.S., Schumacher H.R., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
56. Moltò A., Olivé A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010, 77:102-107.
57. Vergunst C.E., Gerlaq D.M., Dinant H., et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 2007, 46:1773-1778.
58. Lane N.E., Schnitzer T.J., Birbara C.A., et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363:1521-1531.
59. Röhn T.A., Ralvenius W.T., Paul J., et al. A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain. J Immunol 2011, 186:1769-1780.
60. Ugolini G., Marinelli S., Covaceuszach S., et al. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci U S A 2007, 104:2985-2990.